Join today! New study at USC tests effectiveness of newly approved drug to help people with eczema, called Atopic Dermatitis

Atopic Dermatitis is a form of eczema that causes dry, scaly, itchy skin. More than 3 million cases are reported in the U.S. each year. People with this skin condition often have problems with bacterial skin infections caused by a specific bacteria known as, Staph aureus, or just Staph. Patients with chronic eczema often use long-term topical or oral treatments to help control their symptoms. But using these medications over long periods of time can have side effects on the body. The purpose of this study is to test the effectiveness of the drug dupilumab (dupixent), which was recently approved by the Food and Drug Administration (FDA) to offer relief to patients who cannot control their eczema with commonly used topical medications.We want to find out how dupilumab affects the amount of bacteria on the skin and the immune system of the patients, and whether it might cause less side effects. Join us today if you are between 18-65 years old with chronic eczema (Atopic Dermatitis).

Palabras clave: eczema, atopic dermatitis, dupilumab, skin, severe, dermatitis, chronic ad,